Lemaitre Vascular (LMAT) EBIT Margin (2010 - 2026)

Lemaitre Vascular (LMAT) has 17 years of EBIT Margin data on file, last reported at 26.71% in Q1 2026.

• EBIT Margin for Q1 2026 came in at 26.71%, up 562.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 8.17% (up 256.0% YoY), and the FY2025 annual result was 6.33%, up 89.0% from the prior year.
• EBIT Margin grew to 26.71% in Q1 2026 per LMAT's latest filing, from 51.65% in the prior quarter.
• Over five years, EBIT Margin peaked at 33.27% in Q3 2025 and troughed at 51.65% in Q4 2025.
• A 5-year average of 12.92% and a median of 20.04% in 2022 frame the typical range for EBIT Margin.
• The sharpest annual moves came in 2024 and 2025: EBIT Margin plunged 7016 bps in 2024, then surged 929 bps in 2025.
• A 5-year view of EBIT Margin shows it stood at 17.01% in 2022, then rose by 23 bps to 20.88% in 2023, then sank by 336 bps to 49.28% in 2024, then dropped by 5 bps to 51.65% in 2025, then jumped by 152 bps to 26.71% in 2026.
• Business Quant data shows LMAT's EBIT Margin at 26.71% in Q1 2026, 51.65% in Q4 2025, and 33.27% in Q3 2025.